Navigation Links
EndoSphere Inc. Receives Patent for Obesity Treatment
Date:6/15/2011

COLUMBUS, Ohio, June 15, 2011 /PRNewswire/ -- EndoSphere Inc., a medical technology company that holds 23 U.S. and international issued and pending patents, announced today that the U.S. Patent and Trademark Office has issued the company a patent covering the use of its endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes.

U.S. Patent number 7,931,693 titled "Method and Apparatus for Reducing Obesity" describes a noninvasive device that uses the body's natural physiology to regulate appetite and satiety among other potential uses.

"This strong initial patent position, in combination with significant clinical interest, makes EndoSphere an attractive partner in the rapidly growing fields of interventional gastroenterology and obesity treatments," commented James McKinley, EndoSphere CEO.  

Kenneth Binmoeller, M.D., EndoSphere's co-founder and the technology's inventor, commented, "EndoSphere's inventions respond to the urgent need for a less invasive, safer and more physiologic treatment for the growing problem of obesity worldwide."

"Treating obesity is the first target for our technology, the first of several major medical applications for which we plan to develop and commercialize products," added McKinley.

EndoSphere Inc. completed an oversubscribed Series A funding in June 2011.

About EndoSphere Inc.

EndoSphere Inc. is a medical technology company founded in 2006.  The company develops and commercializes devices including the SatiSphere™ duodenal insert, which treats one of the most critical healthcare issues in the world today: obesity and its co-morbidities.  EndoSphere holds 23 U.S. and international issued and pending patents.  EndoSphere is a portfolio company of Broadline Capital, a global private equity investment firm.  For more information, please visit www.EndoSphereInc.com.


'/>"/>
SOURCE EndoSphere Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EndoSphere Inc. Announces Pivotal Financing Led by Broadline Capital
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. CryoCor Receives FDA Approval for Right Atrial Flutter
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
(Date:4/18/2017)... 2017  Cardinal Health (NYSE: CAH ) ... earnings per share (EPS) guidance and providing a preliminary ... conjunction with this morning,s announcement of the planned acquisition ... Insufficiency businesses. Cardinal Health now believes that ... at the bottom of its previous guidance range of ...
(Date:4/18/2017)... DALLAS , April 18, 2017 Viverae ... proud to announce the integration of IBM ® ... platform to deliver targeted communications for a personalized experience. ... meaningful actions on their health in real time. The ... that matter most to members, wherever they are in ...
Breaking Medicine Technology:
(Date:4/24/2017)... RICHEY, Fla. (PRWEB) , ... April 24, 2017 ... ... and Prevention (CDC), rising prescription opioid overdose deaths now claim the lives of ... slashed its civil case filings against drug manufacturers, distributors, pharmacies and prescribers by ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health Management announced ... in people with addiction who are served by MAP’s patient engagement ecosystem. Lief ... that monitors heart and breath rates to identify anxiety levels and can provide ...
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively new statin, ... not known to have significant interactions with antiretroviral therapy (ART). Among people ... and dampen inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Come to ... Hotel, 4200 Jim Walter Blvd, for an educational and exciting 2-day program. , ... our staff hearing this before they approach patients” about the course entitled Ain't Misbehavin': ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Donna Parker, ... but she has not found any of them to be very practical. She wanted ... slowly and easily make changes in their health. It prompted her in writing “ ...
Breaking Medicine News(10 mins):